<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124364">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01873573</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-17316</org_study_id>
    <nct_id>NCT01873573</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Endoscopic Dilation: Triamcinolone Injection</brief_title>
  <official_title>Randomized Controlled Trial of Endoscopic Dilation With or Without Triamcinolone Injection in Patients With Non-malignant Radiation or Anastomotic Esophageal Strictures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if adding triamcinolone (steroid) injection at the
      participant's initial esophagogastroduodenoscopy (EGD) procedure will improve the opening of
      their esophagus and decrease the need for repeat dilations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized two-arms cross-over trial. In this study there are two groups, the
      control group and the triamcinolone treatment group. The cross-over design will apply only
      in the control group when patients are not responding to EGD dilations alone (defined as no
      sustained improvement in baseline dysphagia) and they will be allowed to cross-over to the
      triamcinolone group and undergo 3 successive EGDs with triamcinolone injection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Number of Visits to Receive Esophageal Dilation During the 12 Month Follow-up Period</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The main outcome measured will be number of visits to receive Esophageal Dilation during the 12-month follow-up period. Successful dilation of the stricture for the procedure will be defined as creation of a mucosal tear confirmed by endoscopic visualization after the last dilation is performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final Dysphagia Score</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dysphagia Scoring System: 0 = able to eat normal diet / no dysphagia; 1 = able to swallow some solid foods; 2 = able to swallow only semi solid foods; 3 = able to swallow liquids only; 4 = unable to swallow anything / total dysphagia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dysphagia</condition>
  <arm_group>
    <arm_group_label>Esophagogastroduodenoscopy (EGD) with Dilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care: EGD with dilation alone. If participants are assigned to Arm A and are not showing any clinical improvements as determined by their physician after the first three endoscopic dilation sessions, then they will be crossed over into Arm B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGD with Dilation, plus Triamcinolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of Care: EGD with dilation, plus Triamcinolone injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dilation</intervention_name>
    <description>Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.</description>
    <arm_group_label>Esophagogastroduodenoscopy (EGD) with Dilation</arm_group_label>
    <arm_group_label>EGD with Dilation, plus Triamcinolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Injection</intervention_name>
    <description>After endoscopic dilation is performed, a total of 40-80mg(physician preference) of triamcinolone (40mg/ml) will be injected throughout the stricture under direct visualization.</description>
    <arm_group_label>EGD with Dilation, plus Triamcinolone</arm_group_label>
    <other_name>steroid</other_name>
    <other_name>corticosteroid</other_name>
    <other_name>Kenalog 10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Esophagogastroduodenoscopy (EGD)</intervention_name>
    <description>EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.</description>
    <arm_group_label>Esophagogastroduodenoscopy (EGD) with Dilation</arm_group_label>
    <arm_group_label>EGD with Dilation, plus Triamcinolone</arm_group_label>
    <other_name>flexible endoscope</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who present for EGD with dilation for dysphagia symptoms thought secondary
             to either radiation-induced stricture or anastomotic stricture based on history

        Exclusion Criteria:

          -  Inability to consent for the procedure

          -  Known coagulopathy [International Normalized Ratio (INR) &gt;1.5, Platelets &lt;75 K]

          -  Endoscopic finding of a stricture that is not caused by either radiation or
             anastomotic narrowing

          -  Nasopharyngeal strictures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Klapman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Klapman, M.D.</last_name>
    <phone>813-745-4035</phone>
    <email>jason.klapman@moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muthuasamy Venkataraman, M.D.</last_name>
      <phone>310-267-3636</phone>
      <email>raman@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Muthuasamy Venkataraman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janak Shah, M.D.</last_name>
      <phone>415-600-1151</phone>
      <email>shahj@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Janak Shah, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sachin Wani</last_name>
      <phone>720-848-2786</phone>
      <email>Sachin.wani@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Sachin Wani, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Daniels</last_name>
      <phone>813-745-3960</phone>
      <email>david.daniels@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jason Klapman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Harris, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shivakumar Vignesh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sri Komanduri, M.D.</last_name>
      <phone>312-695-0484</phone>
      <email>koman1973@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sri Komanduri, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation-induced stricture</keyword>
  <keyword>anastomotic stricture</keyword>
  <keyword>esophagogastroduodenoscopy (EGD)</keyword>
  <keyword>dilation</keyword>
  <keyword>steroid injection</keyword>
  <keyword>triamcinolone</keyword>
  <keyword>difficulty swallowing</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deglutition Disorders</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
    <mesh_term>Esophageal Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
